BRIEF-Oncosec Announces Clinical Data Of The Keynote-695 Trial Assessing Tavo-Ep In Combination With Keytruda (Pembrolizumab)

Reuters

2023/04/03

April 3 (Reuters) - OncoSec Medical Inc :

* ONCOSEC ANNOUNCES CLINICAL DATA OF THE KEYNOTE-695 TRIAL ASSESSING TAVO™-EP IN COMBINATION WITH KEYTRUDA® (PEMBROLIZUMAB) IN PATIENTS WITH ADVANCED MELANOMA REFRACTORY TO ANTI-PD-1 TREATMENT

* ONCOSEC MEDICAL INC - PRIMARY ENDPOINT OF ORR PER RECIST V1.1 ASSESSED BY BLINDED INDEPENDENT CENTRAL REVIEW (BICR) WAS NOT MET IN STUDY

* ONCOSEC MEDICAL INC - COMPANY PLANS TO PURSUE TAVO™-EP IN COMBINATION WITH ANTI-PD-1 THERAPY IN NEOADJUVANT MELANOMA SETTING

* ONCOSEC MEDICAL - MEETING WITH FDA TO DISCUSS PHASE 2 RANDOMIZED TRIAL DESIGN, DEVELOPMENT PLANS IN MELANOMA NEOADJUVANT SETTING IS SCHEDULED IN MAY

Source text for Eikon: Further company coverage:

((reuters.briefs@thomsonreuters.com;))

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2324350869"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2324350869\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2324350869?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2023-04-03 19:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2324350869","market":"us","top_or_hot":-1,"title":"BRIEF-Oncosec Announces Clinical Data Of The Keynote-695 Trial Assessing Tavo-Ep In Combination With Keytruda (Pembrolizumab)","media":"Reuters","content":"<html><body><p>April 3 (Reuters) - OncoSec Medical Inc   :</p><p>   * ONCOSEC ANNOUNCES CLINICAL DATA OF THE KEYNOTE-695 TRIAL ASSESSING TAVO™-EP IN COMBINATION WITH KEYTRUDA® (PEMBROLIZUMAB) IN PATIENTS WITH ADVANCED MELANOMA REFRACTORY TO ANTI-PD-1 TREATMENT</p><p>   * ONCOSEC MEDICAL INC - PRIMARY ENDPOINT OF ORR PER RECIST V1.1 ASSESSED BY BLINDED INDEPENDENT CENTRAL REVIEW (BICR) WAS NOT MET IN STUDY</p><p>   * ONCOSEC MEDICAL INC - COMPANY PLANS TO PURSUE TAVO™-EP IN COMBINATION WITH ANTI-PD-1 THERAPY IN NEOADJUVANT MELANOMA SETTING</p><p>   * ONCOSEC MEDICAL - MEETING WITH FDA TO DISCUSS PHASE 2 RANDOMIZED TRIAL DESIGN,  DEVELOPMENT PLANS IN MELANOMA NEOADJUVANT SETTING IS SCHEDULED IN MAY</p><p>Source text for Eikon:    Further company coverage:   </p><p> ((reuters.briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Oncosec Announces Clinical Data Of The Keynote-695 Trial Assessing Tavo-Ep In Combination With Keytruda (Pembrolizumab)</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Oncosec Announces Clinical Data Of The Keynote-695 Trial Assessing Tavo-Ep In Combination With Keytruda (Pembrolizumab)\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2023-04-03 19:31</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p>April 3 (Reuters) - OncoSec Medical Inc   :</p><p>   * ONCOSEC ANNOUNCES CLINICAL DATA OF THE KEYNOTE-695 TRIAL ASSESSING TAVO™-EP IN COMBINATION WITH KEYTRUDA® (PEMBROLIZUMAB) IN PATIENTS WITH ADVANCED MELANOMA REFRACTORY TO ANTI-PD-1 TREATMENT</p><p>   * ONCOSEC MEDICAL INC - PRIMARY ENDPOINT OF ORR PER RECIST V1.1 ASSESSED BY BLINDED INDEPENDENT CENTRAL REVIEW (BICR) WAS NOT MET IN STUDY</p><p>   * ONCOSEC MEDICAL INC - COMPANY PLANS TO PURSUE TAVO™-EP IN COMBINATION WITH ANTI-PD-1 THERAPY IN NEOADJUVANT MELANOMA SETTING</p><p>   * ONCOSEC MEDICAL - MEETING WITH FDA TO DISCUSS PHASE 2 RANDOMIZED TRIAL DESIGN,  DEVELOPMENT PLANS IN MELANOMA NEOADJUVANT SETTING IS SCHEDULED IN MAY</p><p>Source text for Eikon:    Further company coverage:   </p><p> ((reuters.briefs@thomsonreuters.com;))</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CGEM","symbol_name":"Cullinan Therapeutics","start_time":0,"source_url":"http://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2324350869","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2324350869","pubTimestamp":1680521496,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"April 3 (Reuters) - OncoSec Medical Inc   :   * ONCOSEC ANNOUNCES CLINICAL DATA OF THE KEYNOTE-695 T","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CGEM":"Cullinan Therapeutics","BK4534":"瑞士信贷持仓","ONTF":"ON24, Inc.","BK4139":"生物科技","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","LU0861579265.USD":"联博低波幅策略股票基金A","BK4533":"AQR资本管理(全球第二大对冲基金)","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","LU1974910355.USD":"Allianz Thematica Cl AMg DIS USD","LU0122379950.USD":"贝莱德世界健康科学A2","IE00B1BXHZ80.USD":"Legg Mason ClearBridge - US Appreciation A Acc USD","LU0234572021.USD":"高盛美国核心股票组合Acc","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","LU1989771016.USD":"东方汇理环球老龄化投资基金 A2 Acc","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","BK4082":"医疗保健设备","SG9999014559.SGD":"United Income Focus Trust Dis SGD","MRK":"默沙东","BK4559":"巴菲特持仓","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU0266013472.USD":"AXA WF - Framlington Longevity Economy A Cap USD","BK4550":"红杉资本持仓","SG9999001176.USD":"United Global Healthcare Acc USD","LHDX":"Lucira Health, Inc.","BK4588":"碎股","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU1989772923.USD":"CPR Invest - Climate Action A2 Acc USD-H","SG9999014567.USD":"UOB UNITED INCOME FOCUS TRUST FUND (USD) ACC","SANA":"Sana Biotechnology, Inc.","LU2023250843.SGD":"Allianz Thematica Cl AT Acc H2-SGD","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","LU2023250504.SGD":"Allianz Thematica Cl AMg DIS H2-SGD","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU1917777945.USD":"安联专题基金Cl AT Acc","BK4007":"制药","LABP":"Landos Biopharma, Inc.","SG9999002232.USD":"Allianz Global High Payout USD","BK4196":"保健护理服务","SG9999015358.SGD":"United Income Focus Trust Dis SGD-H","BK4585":"ETF&股票定投概念","BK4023":"应用软件","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","SG9999015341.SGD":"United Income Focus Trust Acc SGD-H","SG9999002224.SGD":"Allianz Global High Payout SGD","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","SG9999014542.SGD":"United Income Focus Trust Acc SGD","LU2106854487.HKD":"ALLIANZ THEMATICA \"AMG\" (HKD) INC"},"translate_title":"简介——Oncosec公布Keynote-695试验的临床数据，该试验评估Tavo-Ep与Keytruda（彭布罗利珠单抗）的联合应用","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CGEM":0.83,"LHDX":0.83,"ONTF":0.9,"MRK":1,"ONCS":0.9,"LABP":0.83,"SANA":0.83},"content_text":"April 3 (Reuters) - OncoSec Medical Inc   :   * ONCOSEC ANNOUNCES CLINICAL DATA OF THE KEYNOTE-695 TRIAL ASSESSING TAVO™-EP IN COMBINATION WITH KEYTRUDA® (PEMBROLIZUMAB) IN PATIENTS WITH ADVANCED MELANOMA REFRACTORY TO ANTI-PD-1 TREATMENT   * ONCOSEC MEDICAL INC - PRIMARY ENDPOINT OF ORR PER RECIST V1.1 ASSESSED BY BLINDED INDEPENDENT CENTRAL REVIEW (BICR) WAS NOT MET IN STUDY   * ONCOSEC MEDICAL INC - COMPANY PLANS TO PURSUE TAVO™-EP IN COMBINATION WITH ANTI-PD-1 THERAPY IN NEOADJUVANT MELANOMA SETTING   * ONCOSEC MEDICAL - MEETING WITH FDA TO DISCUSS PHASE 2 RANDOMIZED TRIAL DESIGN,  DEVELOPMENT PLANS IN MELANOMA NEOADJUVANT SETTING IS SCHEDULED IN MAYSource text for Eikon:    Further company coverage:    ((reuters.briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}